Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Return on Sales for 10 consecutive years, with 0.59% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 320.0% to 0.59% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.85% through Dec 2025, down 83.0% year-over-year, with the annual reading at 0.85% for FY2025, 83.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.59% at Ultragenyx Pharmaceutical, up from 1.13% in the prior quarter.
  • The five-year high for Return on Sales was 3.82% in Q4 2023, with the low at 2.7% in Q3 2022.
  • Average Return on Sales over 5 years is 0.91%, with a median of 1.39% recorded in 2021.
  • The sharpest move saw Return on Sales surged 532bps in 2023, then plummeted -320bps in 2025.
  • Over 5 years, Return on Sales stood at 1.5% in 2021, then decreased by 0bps to 1.5% in 2022, then soared by 354bps to 3.82% in 2023, then tumbled by -32bps to 2.6% in 2024, then tumbled by -123bps to 0.59% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.59%, 1.13%, and 0.69% for Q4 2025, Q3 2025, and Q2 2025 respectively.